Inventiva (IVA) Income from Continuing Operations (2019 - 2025)
Inventiva's (IVA) quarterly Income from Continuing Operations came in at 880664.64 in Q2 2025, up 1268.27% year-on-year from 64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from 74801.68 in Q4 2024.
Inventiva (IVA) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Inventiva's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 880664.64 for Q2 2025.
- On a quarterly basis, Income from Continuing Operations rose 1268.27% year-over-year to 880664.64 in Q2 2025; TTM through Jun 2025 was 485166.53, a 171.52% increase from a year earlier, with the FY2025 full-year figure at 411824626.98, down 100523.69% from the prior year.
- Income from Continuing Operations grew to 880664.64 in Q2 2025 per IVA's latest filing, from 74801.68 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 880664.64 in Q2 2025 and bottomed at 11911448.78 in Q2 2021.
- The 5-year median for Income from Continuing Operations is 178852.68 (2022), against an average of 2077624.3.
- Across the five-year window, Income from Continuing Operations dropped 22.83% in 2021 and jumped 1268.27% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11911448.78 in 2021, then soared by 98.03% to 234656.89 in 2022, then decreased by 4.54% to 245314.3 in 2023, then surged by 69.51% to 74801.68 in 2024, then soared by 1277.33% to 880664.64 in 2025.
- Per Business Quant, the three latest IVA Income from Continuing Operations figures stand at 880664.64 (Q2 2025), 74801.68 (Q4 2024), and 75382.13 (Q2 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 880,664.64 |
| Dec 31, 2024 | -74,801.68 |
| Jun 30, 2024 | -75,382.13 |
| Dec 31, 2023 | -245,314.30 |
| Jun 30, 2023 | -123,048.46 |
| Dec 31, 2022 | -234,656.89 |
| Jun 30, 2021 | -11.91 Mn |
| Mar 31, 2021 | -4.84 Mn |
| Dec 31, 2020 | -35.43 Mn |
| Jun 30, 2020 | -9.70 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.34 Mn |